GLP-1 Medications for PCOS: What the Evidence Shows About Weight, Insulin, and Ovulation

The Question Researchers Are Asking

Women with PCOS are increasingly asking about semaglutide and similar drugs. The obvious benefit is weight loss. The more interesting question is whether these medications also help PCOS through other routes—especially insulin resistance—and what that means for cycles and fertility.

The honest answer: the evidence is promising but still thin. Here's what we know, and what we don't, for the estimated 10-13% of reproductive-age women living with polycystic ovary syndrome.

What PCOS Actually Does to Your Metabolism

PCOS isn't just a reproductive issue. It's fundamentally a metabolic one.

Insulin resistance is a core feature of PCOS, and it can occur even in women without excess weight. Cells don't respond efficiently to insulin, so the pancreas pumps out more. This hyperinsulinemia then pushes the ovaries to produce excess androgens—testosterone and its relatives. The result? Irregular periods, difficulty ovulating, acne, unwanted hair growth.

The traditional approach was straightforward: lose weight, improve insulin sensitivity, restore hormonal balance. And it can work—in women with higher weight, even modest weight loss of around 5-10% can produce meaningful clinical improvements.

But researchers have wondered whether GLP-1 medications do more than move the scale.

What the Trials Actually Show

The best available summaries are meta-analyses of small randomized trials. A 2023 meta-analysis of 11 trials (840 women) found that GLP-1 receptor agonists were associated with higher natural pregnancy rates (risk ratio 1.72) and better menstrual regularity, along with improvements in insulin resistance (HOMA-IR), BMI, and waist circumference, compared with control treatments.

A 2026 meta-analysis in the European Journal of Endocrinology, also of 11 trials, was more cautious. GLP-1 drugs added modest short-term weight loss—about 1.4 BMI points more than controls, with low certainty—while the evidence on glucose, insulin, hirsutism, and menstrual regularity was insufficient to draw conclusions.

And the systematic review that informed the 2023 international PCOS guideline concluded that published data on anti-obesity medications in PCOS are very limited. In short: weight loss is well documented, but large weight-independent effects on ovulation have not been established.

How GLP-1 Could Act on Insulin Resistance

GLP-1 medications act on several systems at once, not only appetite.

In the pancreas, GLP-1 enhances glucose-dependent insulin secretion and suppresses glucagon, which helps control blood sugar after meals. Over time, together with weight loss, insulin resistance tends to improve, which may lower the high insulin levels that drive excess androgen production.

In the liver, GLP-1 signaling decreases glucose production. Your liver normally releases stored glucose between meals, but in insulin-resistant states, it overdoes this. GLP-1 medications help normalize this process.

How much of this happens independently of weight loss in PCOS specifically isn't known—most trials weren't designed to separate the two.

What About Ovulation and Fertility?

For women trying to conceive, the timing question is crucial. When can you actually expect cycles to normalize?

There isn't good data yet on exactly when cycles normalize. In the 2023 meta-analysis, GLP-1 treatment was associated with better menstrual regularity and higher natural pregnancy rates, but the trials were small, short, and varied widely.

Lifestyle change remains the foundation. The 2023 international guideline recommends healthy lifestyle measures for everyone with PCOS and considers anti-obesity medications as an addition for adults with higher weight.

Tirzepatide vs. Semaglutide: The PCOS Comparison

Tirzepatide (Mounjaro, Zepbound) works on both GLP-1 and GIP receptors. Does this dual action translate to better PCOS outcomes?

There's no head-to-head trial in PCOS. According to a 2026 evidence review, liraglutide has the most PCOS-specific evidence, semaglutide data remain sparse, and tirzepatide data in PCOS are still early.

In people with obesity generally, tirzepatide produced more weight loss than semaglutide—20.2% versus 13.7% over 72 weeks in the SURMOUNT-5 trial. Whether that translates into better PCOS outcomes hasn't been tested.

What About Androgen Levels Specifically?

Excess androgens cause many of PCOS's visible symptoms—hirsutism, acne, hair thinning. How quickly do these hormones respond?

The evidence on androgens is mixed. In the 2023 meta-analysis, GLP-1 drugs increased sex hormone-binding globulin (SHBG) and slightly lowered total testosterone compared with controls, but on their own they weren't better than metformin for free testosterone or DHEA-S.

Because hair grows in long cycles, any improvement in unwanted hair takes months to show.

If androgen symptoms are prominent, other treatments—such as combined oral contraceptives or anti-androgens—are often still needed. Discuss options with your clinician.

Practical Considerations for PCOS Treatment

Starting a GLP-1 medication for PCOS involves some specific considerations beyond general weight management.

No GLP-1 medication is approved specifically to treat PCOS; they're prescribed for weight management or type 2 diabetes when those criteria are met. Dosing follows the standard label schedule. For semaglutide for weight management (Wegovy), that means 0.25 mg weekly for the first four weeks, increasing every four weeks to the 2.4 mg maintenance dose; if a dose step isn't tolerated, prescribers can delay the increase.

Monitoring usually includes weight, glucose markers, and side effects. Low blood sugar is uncommon when a GLP-1 drug is combined with metformin alone, but the risk rises when it's combined with insulin or a sulfonylurea, which may need dose adjustments.

For those trying to conceive, the semaglutide (Wegovy) label advises stopping at least 2 months before a planned pregnancy because of its long washout period, and human pregnancy data remain limited. If you take tirzepatide and use oral contraceptives, its label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase, because it can reduce how well oral contraceptives are absorbed.

Who Responds Best?

Research hasn't yet identified reliable predictors of who responds best.

Women with PCOS and higher weight have the strongest evidence of benefit, because weight loss itself improves PCOS features. GLP-1 drugs haven't been well studied in lean PCOS, so expectations—and the decision to use them—should be discussed carefully with a clinician.

The Bigger Picture for PCOS Management

GLP-1 medications aren't a cure for PCOS. They're a tool—an increasingly powerful one—that addresses the metabolic roots of the condition through multiple mechanisms.

The possibility that these medications act on insulin resistance as well as weight helps explain researchers' interest. Combining GLP-1 medications with other interventions (metformin, lifestyle changes, anti-androgens) might add benefits, but combinations need more study.

For the millions of women managing PCOS, the practical takeaway is realistic expectations: reliable help with weight, possible improvements in insulin resistance and cycles, and uncertain effects on androgens and fertility. Individual responses vary.

The research continues, including trials of semaglutide and tirzepatide in women with PCOS. The results will likely shape treatment guidelines over the next few years.